

CLAIMS

- Sub B2
1. A gene delivery vehicle comprising a nucleic acid molecule encoding apoptin-like activity.
 2. A gene delivery vehicle according to claim 1 additionally comprising a modified translation initiation site directly upstream the ATG-initiation codon of said nucleic acid molecule.
 3. A gene delivery vehicle according to claim 2 wherein said translation initiation site comprises the nucleic acid sequence GCCAAC.
 4. A gene delivery vehicle comprising a nucleic acid molecule encoding VP2-like activity.
 5. A gene delivery vehicle according to claim 4 additionally comprising a modified translation initiation site directly upstream the ATG-initiation codon of said nucleic acid molecule.
 6. A gene delivery vehicle according to ~~any of claims 1 to 3~~ ^{Claim 1} additionally comprising a nucleic acid molecule encoding VP2-like activity.
 7. A gene delivery vehicle according to claim 6 additionally comprising a modified translation initiation site directly upstream the ATG-initiation codon of the nucleic acid molecule encoding VP2-like activity.
 8. A gene delivery vehicle according to any of claims 1 to 7 which is a virus.
 9. A gene delivery vehicle according to claim 8 which is a replication-defective virus.
 10. A gene delivery vehicle according to claim 8 or 9 which is an adenovirus.
 11. A gene delivery vehicle according to claim 8 or 9 which is a retrovirus.
 12. A gene delivery vehicle according to ~~any of claims 1 to 11~~ ^{Claim 6} which additionally comprises at least one target molecule
- Sub B3

sub B3
13. A gene delivery vehicle according to claim 12 wherein the target molecule is reactive with a tumor cell surface receptor.

sub B5
5a
14. A host cell comprising a gene delivery vehicle according to ~~any of the claims 1-13.~~ CLAIM 13

sub B4
15. A host cell according to claim 14 which is a helper or packaging cell.

16. A host cell according to claim 14 which is selected from the group of HEK;293, HER;911, PER.C6, Psi-2 and PA317 cells.

10a
u
17. Use of a gene delivery vehicle according to ~~any of claims 1-13~~ CLAIM 13 in cancer treatment.

18. Use of a gene delivery vehicle according to claim 17 in combination with conventional (chemo)therapy.

a
15a
19. Use of a gene delivery vehicle according to ~~any of claims 1-13~~ CLAIM 13 for the treatment of hyperplasia, metaplasia and dysplasia.

a
a
20. Use of a gene delivery vehicle according to ~~any of claims 1-13~~ CLAIM 13 in diagnosis.

20
21. Use of a gene delivery vehicle according to claim 20 in the in vitro detection of transformed, or cancerous, or hyperplastic, metaplastic or dysplastic cells.

Add B5

Add E4